Abeona Therapeutics Inc.
ABEOAbeona Therapeutics Inc. in brief
Abeona Therapeutics Inc. is a listed company in the Biotechnology industry, based in Texas, USA. It was founded in 1974. Its market value was $261 M on 30 October 2026, which makes it the 15,315th largest listed company in the world and the 2,985th largest in the USA on this site. In the year to December 2025 it had sales of $6 M and a net profit of $71 M. It employs about 226 people and Vishwas Seshadri is its chief executive. Its largest product and service lines by sales in 2025 were License (58%). Its shares trade under the symbol ABEO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Abeona Therapeutics Inc.
ZEVASKYN® is manufactured at our current Good Manufacturing Practices manufacturing facility in Cleveland, Ohio. Treatments are available through ZEVASKYN® qualified treatment centers, a network of centers that are selected based on their expertise in cell and gene therapy and trained to administer ZEVASKYN®. As of March 2026, we have activated 4 qualified treatment centers and are in discussions with additional centers as we continue to expand the ZEVASKYN® qualified treatment network.
The Company’s development portfolio also features adeno-associated virus-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids. Abeona’s novel AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
From the company's annual report filed with the US SEC: read the report
Abeona Therapeutics Inc. timeline
- 1974
- 🏁· approximateFounded
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1996
- ✎Renamed Access Pharmaceuticals IncFormerly Chemex Pharmaceuticals Inc.
- 2014
- ✎Renamed Plasmatech Biopharmaceuticals IncFormerly Access Pharmaceuticals Inc.
- 2015
- ✎Renamed Abeona Therapeutics Inc.Formerly Plasmatech Biopharmaceuticals Inc.
- 2020
- 💰Record revenue of $10 millionFY2020, the highest of the 6 years on record.
Events of Abeona Therapeutics Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,945 (Jan 2020) · #3,401 (Jan 2021) · #4,954 (Jan 2022) · #4,897 (Dec 2022) · #4,425 (Jul 2023) · #3,469 (Jan 2024) · #1,579 (Mar 2026) · #2,774 (Aug 2026) · #2,931 (Oct 2026) · #2,989 (Oct 2026)
Key ratios
- P/E ratio
- 3.7×
- Price / sales
- 44.8×
- Price / book
- 1.6×
- Free cash flow yield
- -32.4%
- Net margin
- 1223.0%
- Operating margin
- -1536.9%
- Return on equity
- 44.7%
- Liabilities / assets
- 27.5%
- Net debt
- $-58M
- Revenue growth
- +66.3%
- R&D / revenue
- 460.7%
- Revenue per employee
- $26 K
- Profit per employee
- $315 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $6M | — | $-89M | $71M | 1223.0% |
| Dec 2024 | — | — | $-64M | $-64M | — |
| Dec 2023 | $4M | +148.2% | $-47M | $-54M | -1548.3% |
| Dec 2022 | $1M | -53.0% | $-51M | $-40M | -2815.6% |
| Dec 2021 | $3M | -70.0% | $-90M | $-85M | -2831.3% |
| Dec 2020 | $10M | — | $-81M | $-84M | -842.3% |
| Dec 2019 | — | — | $-77M | $-76M | — |
| Dec 2018 | $3M | — | $-58M | $-57M | -1889.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-76M | $8M | $-84M | $1.01 | — |
| Dec 2024 | $-56M | $2M | $-58M | $-1.55 | — |
| Dec 2023 | $-37M | $0M | $-37M | $-2.53 | — |
| Dec 2022 | $-43M | $0M | $-44M | $-5.53 | — |
| Dec 2021 | $-66M | $4M | $-70M | $-0.86 | — |
| Dec 2020 | $-35M | $1M | $-36M | $-0.91 | — |
| Dec 2019 | $-63M | $6M | $-69M | $-1.51 | — |
| Dec 2018 | $-39M | $9M | $-48M | $-1.19 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $13M, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 9, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Unregistered share sale · Regulation FD disclosure
- Sep 15, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 12, 20268-KCurrent reportShareholder vote
- Jun 12, 20268-KCurrent reportDirectors or officers changed
- Jun 10, 20268-KCurrent reportRegulation FD disclosure
- Jun 4, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
Official filings of Abeona Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $6 M
- Operating income
- $-89 M
- Net income
- $71 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $220 M
- Total liabilities
- $60 M
- Total equity
- $159 M
As of December-2025
Top 100 institutional investors in Abeona Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 5,410,643 | -4,862,337 (-47.33%) | 9.47% | $28 M | Nov 13, 2026 |
| 2 | Cable Car Capital, LP | 3,600,000 | +592,671 (+19.71%) | 6.30% | $19 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 3,376,695 | +24,221 (+0.72%) | 5.91% | $18 M | Nov 13, 2026 |
| 4 | Rubric Capital Management LP | 3,339,707 | +2,730,936 (+448.60%) | 5.84% | $18 M | Nov 16, 2026 |
| 5 | AIGH Capital Management LLC | 2,900,000 | -87,000 (-2.91%) | 5.07% | $15 M | Nov 2, 2026 |
| 6 | Vanguard Capital Management LLC | 2,137,768 | -73,665 (-3.33%) | 3.74% | $11 M | Nov 13, 2026 |
| 7 | J. Goldman & Co LP | 1,517,152 | +838,979 (+123.71%) | 2.65% | $8 M | Nov 16, 2026 |
| 8 | AWM Investment Company, Inc. | 1,487,130 | +1,000 (+0.07%) | 2.60% | $8 M | Nov 13, 2026 |
| 9 | Kennedy Capital Management LLC | 1,330,788 | +90,717 (+7.32%) | 2.33% | $7 M | Nov 13, 2026 |
| 10 | Geode Capital Management, LLC | 1,325,534 | +64,444 (+5.11%) | 2.32% | $7 M | Nov 6, 2026 |
| 11 | Goldman Sachs Group Inc | 1,159,504 | -65,302 (-5.33%) | 2.03% | $6 M | Nov 16, 2026 |
| 12 | State Street Corp | 1,051,382 | +11,154 (+1.07%) | 1.84% | $6 M | Nov 12, 2026 |
| 13 | Propel Bio Management, LLC | 956,007 | -27,063 (-2.75%) | 1.67% | $5 M | Nov 13, 2026 |
| 14 | Citigroup Inc | 874,649 | +326,349 (+59.52%) | 1.53% | $5 M | Nov 4, 2026 |
| 15 | Bank Of America Corp /de/ | 730,211 | +357,805 (+96.08%) | 1.28% | $4 M | Nov 16, 2026 |
| 16 | Silverarc Capital Management, LLC | 693,441 | +83,034 (+13.60%) | 1.21% | $4 M | Nov 12, 2026 |
| 17 | Barclays PLC | 602,576 | +246,149 (+69.06%) | 1.05% | $3 M | Nov 6, 2026 |
| 18 | Nan Fung Trinity (HK) LTD | 552,270 | -404,500 (-42.28%) | 0.97% | $3 M | Nov 6, 2026 |
| 19 | Woodline Partners LP | 551,837 | New | 0.97% | $3 M | Nov 16, 2026 |
| 20 | Northern Trust Corp | 538,350 | -14,280 (-2.58%) | 0.94% | $3 M | Nov 16, 2026 |
| 21 | Panagora Asset Management Inc | 527,147 | +118,072 (+28.86%) | 0.92% | $3 M | Nov 12, 2026 |
| 22 | National Bank Of Canada /fi/ | 500,000 | 0 (0.00%) | 0.87% | $3 M | Nov 16, 2026 |
| 23 | Morgan Stanley | 442,801 | +77,242 (+21.13%) | 0.77% | $2 M | Nov 13, 2026 |
| 24 | Diametric Capital, LP | 403,436 | -351,585 (-46.57%) | 0.71% | $2 M | Nov 16, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 334,779 | -13,239 (-3.80%) | 0.59% | $2 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Portfolio Management LLC | 313,394 | +21,741 (+7.45%) | 0.55% | $2 M | Nov 13, 2026 |
| 27 | Stonepine Capital Management, LLC | 282,016 | -275,268 (-49.39%) | 0.49% | $1 M | Nov 13, 2026 |
| 28 | Simplify Asset Management Inc. | 276,333 | -69,083 (-20.00%) | 0.48% | $1 M | Oct 27, 2026 |
| 29 | ExodusPoint Capital Management, LP | 242,174 | +29,849 (+14.06%) | 0.42% | $1 M | Nov 16, 2026 |
| 30 | Bank of New York Mellon Corp | 207,526 | +3,280 (+1.61%) | 0.36% | $1 M | Nov 5, 2026 |
| 31 | UBS Group AG | 205,312 | -17,967 (-8.05%) | 0.36% | $1 M | Nov 10, 2026 |
| 32 | Corient Private Wealth LP | 198,677 | +108,769 (+120.98%) | 0.35% | $1 M | Nov 16, 2026 |
| 33 | Dimensional Fund Advisors LP | 194,201 | +159,830 (+465.01%) | 0.34% | $1 M | Nov 4, 2026 |
| 34 | Y-Intercept (Hong Kong) Ltd | 168,334 | +95,961 (+132.59%) | 0.29% | $1 M | Oct 16, 2026 |
| 35 | Millennium Management LLC | 163,890 | -47,445 (-22.45%) | 0.29% | $1 M | Nov 16, 2026 |
| 36 | Charles Schwab Investment Management Inc | 136,043 | +15,529 (+12.89%) | 0.24% | $1 M | Nov 16, 2026 |
| 37 | Two Sigma Investments, LP | 124,674 | +43,937 (+54.42%) | 0.22% | $1 M | Nov 16, 2026 |
| 38 | SEI Investments Co | 112,995 | +7,435 (+7.04%) | 0.20% | $1 M | Nov 10, 2026 |
| 39 | Palo Alto Investors LP | 108,865 | 0 (0.00%) | 0.19% | $1 M | Nov 16, 2026 |
| 40 | Nuveen, LLC | 94,148 | +11,522 (+13.94%) | 0.16% | $0 M | Nov 10, 2026 |
| 41 | Birchview Capital, LP | 90,700 | New | 0.16% | $0 M | Nov 13, 2026 |
| 42 | Pale Fire Capital SE | 76,844 | -5,101 (-6.22%) | 0.13% | $0 M | Nov 13, 2026 |
| 43 | American Century Companies Inc | 74,056 | +27,641 (+59.55%) | 0.13% | $0 M | Nov 12, 2026 |
| 44 | LPL Financial LLC | 70,419 | +624 (+0.89%) | 0.12% | $0 M | Nov 6, 2026 |
| 45 | BNP Paribas Financial Markets | 69,924 | +62,934 (+900.34%) | 0.12% | $0 M | Nov 12, 2026 |
| 46 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 60,453 | +57,041 (+1671.78%) | 0.11% | $0 M | Nov 16, 2026 |
| 47 | Jain Global LLC | 60,095 | +31,210 (+108.05%) | 0.11% | $0 M | Nov 16, 2026 |
| 48 | Caption Management, LLC | 60,000 | New | 0.10% | $0 M | Nov 16, 2026 |
| 49 | Rhumbline Advisers | 55,388 | -1,363 (-2.40%) | 0.10% | $0 M | Nov 10, 2026 |
| 50 | Rangeley Capital, LLC | 51,300 | -6,800 (-11.70%) | 0.09% | $0 M | Nov 16, 2026 |
| 51 | Diadema Partners LP | 51,117 | New | 0.09% | $0 M | Nov 16, 2026 |
| 52 | Atom Investors LP | 50,717 | +25,847 (+103.93%) | 0.09% | $0 M | Nov 16, 2026 |
| 53 | Harbor Capital Advisors, Inc. | 50,035 | +11,747 (+30.68%) | 0.09% | $0 M | Oct 22, 2026 |
| 54 | Seven Fleet Capital Management LP | 48,745 | New | 0.09% | $0 M | Nov 16, 2026 |
| 55 | Campbell & CO Investment Adviser LLC | 47,834 | New | 0.08% | $0 M | Nov 13, 2026 |
| 56 | AQR Capital Management LLC | 42,734 | -24,329 (-36.28%) | 0.07% | $0 M | Nov 16, 2026 |
| 57 | FMR LLC | 41,457 | -97,040 (-70.07%) | 0.07% | $0 M | Nov 10, 2026 |
| 58 | Deutsche Bank AG\ | 41,381 | -6,177 (-12.99%) | 0.07% | $0 M | Nov 6, 2026 |
| 59 | Price T Rowe Associates Inc /MD/ | 39,023 | +6,432 (+19.74%) | 0.07% | $0 M | Nov 16, 2026 |
| 60 | Alliancebernstein L.P. | 37,940 | -10,010 (-20.88%) | 0.07% | $0 M | Nov 16, 2026 |
| 61 | Wealth Effects LLC | 30,950 | +3,700 (+13.58%) | 0.05% | $0 M | Oct 23, 2026 |
| 62 | Creative Planning | 28,746 | +8,243 (+40.20%) | 0.05% | $0 M | Nov 2, 2026 |
| 63 | Prelude Capital Management, LLC | 28,304 | -27,634 (-49.40%) | 0.05% | $0 M | Nov 16, 2026 |
| 64 | Russell Investments Group, Ltd. | 26,902 | -1,515 (-5.33%) | 0.05% | $0 M | Nov 6, 2026 |
| 65 | Persistent Asset Partners Ltd | 26,010 | +265 (+1.03%) | 0.05% | $0 M | Nov 13, 2026 |
| 66 | Jpmorgan Chase & Co | 25,932 | -24,573 (-48.65%) | 0.05% | $0 M | Nov 12, 2026 |
| 67 | MetLife Investment Management, LLC | 24,766 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 68 | Riverwater Partners LLC | 24,304 | 0 (0.00%) | 0.04% | $0 M | Nov 3, 2026 |
| 69 | Aigen Investment Management, LP | 23,871 | New | 0.04% | $0 M | Nov 16, 2026 |
| 70 | Invesco Ltd. | 22,265 | -1,459 (-6.15%) | 0.04% | $0 M | Nov 12, 2026 |
| 71 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 21,193 | +1,083 (+5.39%) | 0.04% | $0 M | Nov 16, 2026 |
| 72 | Pinnacle Financial Group, Inc. | 19,000 | — | 0.03% | $0 M | Nov 16, 2026 |
| 73 | Vanguard Global Advisers, LLC | 18,810 | +202 (+1.09%) | 0.03% | $0 M | Nov 13, 2026 |
| 74 | Citadel Advisors LLC | 16,898 | -242,503 (-93.49%) | 0.03% | $0 M | Nov 16, 2026 |
| 75 | Legato Capital Management LLC | 16,830 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 76 | Manufacturers Life Insurance Company, The | 13,615 | +1,371 (+11.20%) | 0.02% | $0 M | Nov 13, 2026 |
| 77 | Natixis | 13,340 | -6,291 (-32.05%) | 0.02% | $0 M | Nov 6, 2026 |
| 78 | Squarepoint Ops LLC | 12,550 | New | 0.02% | $0 M | Nov 9, 2026 |
| 79 | Aries Wealth Management | 12,500 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 80 | Public Employees Retirement System Of Ohio | 11,938 | New | 0.02% | $0 M | Nov 16, 2026 |
| 81 | D. E. Shaw & Co., Inc. | 11,622 | -45,478 (-79.65%) | 0.02% | $0 M | Nov 16, 2026 |
| 82 | Police & Firemen's Retirement System of New Jersey | 11,005 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 83 | Brevan Howard Capital Management LP | 10,939 | New | 0.02% | $0 M | Nov 16, 2026 |
| 84 | MAI Capital Management | 10,333 | +2,413 (+30.47%) | 0.02% | $0 M | Nov 12, 2026 |
| 85 | Savant Capital, LLC | 10,318 | New | 0.02% | $0 M | Nov 6, 2026 |
| 86 | Tower Research Capital LLC (TRC) | 10,290 | +6,238 (+153.95%) | 0.02% | $0 M | Nov 16, 2026 |
| 87 | Wells Fargo & Company/mn | 8,933 | -27,655 (-75.58%) | 0.02% | $0 M | Nov 16, 2026 |
| 88 | Global Retirement Partners, LLC | 4,978 | +4,536 (+1026.24%) | 0.01% | $0 M | Nov 10, 2026 |
| 89 | Allworth Financial LP | 4,813 | +161 (+3.46%) | 0.01% | $0 M | Nov 17, 2026 |
| 90 | Ameritas Investment Partners, Inc. | 4,459 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 91 | Legal & General Group Plc | 3,975 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 92 | PNC Financial Services Group, Inc. | 2,864 | +2,295 (+403.34%) | 0.01% | $0 M | Nov 6, 2026 |
| 93 | Nisa Investment Advisors, LLC | 2,571 | -2,000 (-43.75%) | 0.00% | $0 M | Oct 20, 2026 |
| 94 | Royal Bank Of Canada | 2,349 | -1,227 (-34.31%) | 0.00% | $0 M | Nov 16, 2026 |
| 95 | GAMMA Investing LLC | 2,012 | +261 (+14.91%) | 0.00% | $0 M | Oct 8, 2026 |
| 96 | Arax Advisory Partners | 1,829 | -1,866 (-50.50%) | 0.00% | $0 M | Nov 12, 2026 |
| 97 | New York State Common Retirement Fund | 1,700 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 98 | Osaic Holdings, Inc. | 1,361 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 99 | Rockefeller Capital Management L.P. | 1,250 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 100 | Jones Financial Companies Lllp | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Abeona Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.53 M | $9 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.19 M | $7 M | 2.1% | <0.01% | +3.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 627,769 | $4 M | 1.1% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 478,770 | $3 M | 0.84% | <0.01% | +4.9% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 409,560 | $3 M | 0.72% | 0.02% | +1553% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 263,003 | $2 M | 0.46% | <0.01% | −3.2% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 235,632 | $1 M | 0.41% | <0.01% | +9.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 145,114 | $1 M | 0.25% | 0.06% | +26% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 133,069 | $1 M | 0.23% | 0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 119,122 | $1 M | 0.21% | <0.01% | +2.3% | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 115,525 | $1 M | 0.20% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 105,082 | $1 M | 0.18% | <0.01% | +2.0% | Jul 31, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc. | 95,434 | $1 M | 0.17% | 0.08% | −2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 98,619 | $1 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 75,671 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 77,084 | $0 M | 0.13% | <0.01% | +6.2% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 60,909 | $0 M | 0.11% | 0.02% | +1556% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 56,719 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 50,057 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Harbor Human Capital Factor US Small Cap ETFHarbor Capital Advisors, Inc. | 38,309 | $0 M | 0.07% | 0.14% | +8.5% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 40,172 | $0 M | 0.07% | 0.01% | +6.8% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 33,384 | $0 M | 0.06% | <0.01% | +276% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 32,763 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 29,500 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 27,928 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 26,610 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 26,710 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 26,337 | $0 M | 0.05% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 23,850 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 22,200 | $0 M | 0.04% | <0.01% | +57% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 20,862 | $0 M | 0.04% | <0.01% | +9.0% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 20,082 | $0 M | 0.04% | <0.01% | +9.3% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 20,045 | $0 M | 0.04% | 0.01% | +100% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 19,845 | $0 M | 0.03% | <0.01% | +6.8% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 18,970 | $0 M | 0.03% | <0.01% | +112% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 18,970 | $0 M | 0.03% | <0.01% | +112% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 16,656 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,352 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 14,806 | $0 M | 0.03% | 0.02% | −4.5% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,339 | $0 M | 0.03% | <0.01% | −2.1% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 11,637 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,791 | $0 M | 0.02% | 0.03% | +20% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 9,363 | $0 M | 0.02% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,352 | $0 M | 0.01% | 0.01% | +7.3% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 8,480 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,326 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 7,346 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,684 | $0 M | 0.01% | 0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,680 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,662 | $0 M | 0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 6,400 | $0 M | 0.01% | <0.01% | +1220% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,794 | $0 M | 0.01% | <0.01% | +4.6% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,553 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,114 | $0 M | <0.01% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 4,715 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,459 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,700 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 4,446 | $0 M | <0.01% | <0.01% | +161% | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,834 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,668 | $0 M | <0.01% | <0.01% | +9.2% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,618 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,220 | $0 M | <0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,341 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 2,915 | $0 M | <0.01% | <0.01% | +1493% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 2,912 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,159 | $0 M | <0.01% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,913 | $0 M | <0.01% | <0.01% | −45% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 1,704 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,706 | $0 M | <0.01% | <0.01% | −37% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,688 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,554 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,383 | $0 M | <0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,404 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,089 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 916 | $0 M | <0.01% | <0.01% | −3.1% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 509 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 272 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 77 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Abeona Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Faith L. CharlesDirector | Buy | +15,000 | $2.290 | $34 K | 191,407 | Form 4 |
| filed | Vishwas SeshadriChief Executive Officer, Director | Sell | -19,608 | $5.160 | $101 K | 1.29 M | Form 4 |
| filed | Madhav VasanthavadaChief Commercial Officer | Sell | -4,902 | $5.160 | $25 K | 285,721 | Form 4 |
| filed | Brendan M. O'MalleySVP, Chief Legal Officer | Sell | -6,727 | $5.160 | $35 K | 421,226 | Form 4 |
| filed | Joseph Walter VazzanoChief Financial Officer | Sell | -9,191 | $5.160 | $47 K | 482,888 | Form 4 |
| filed | Mark AlvinoDirector | Sell | -15,000 | $5.860 | $88 K | 62,065 | Form 4 |
| filed | Joseph Walter VazzanoChief Financial Officer | Sell | -1,478 | $6.530 | $10 K | 492,079 | Form 4 |
| filed | Vishwas SeshadriChief Executive Officer, Director | Sell | -67,971 | $6.960 | $473 K | 1.31 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Abeona Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 75,205 shares at $4.56
- : 12,899 shares at $4.55
- : 1,283 shares at $4.45
- : 1,153 shares at $4.31
- : 9,601 shares at $4.40
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Abeona Therapeutics Inc. scorecard#
Passes 10 of the 18 checks that could be worked out: strongest in valuation (3 of 5), weakest in profitability (2 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation3 of 5
- ✓P/E below its peers' median3.7×P/E 3.7× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median44.8×Price to sales 44.8× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-32.4%Free cash flow is -32.4% of the market value.
- ✓Earnings yield above the 10-year Treasury yield27.3%Earnings yield 27.3% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year1.01 vs -1.55Diluted EPS 1.01 in fiscal 2025 against -1.55 the year before (report's currency).
- ✓Net income higher than five years earlier$71 M$71 M in fiscal 2025 against -$84 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 4
- ✓Profitable in the newest year$71 MNet income $71 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✓Return on equity above 15%70.0%70.0% in fiscal 2025.
- ✗Return on invested capital above 10%-127.2%-127.2% in fiscal 2025.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities6.9×Current ratio 6.93 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.13 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $58 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-23.9×Operating income -23.9 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-2.50Z-score -2.50 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year61.1%Diluted shares up 61.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Abeona Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 5.8—100% | — | 3.5+148%100% | 1.4−52.9%100% | 3.0−70.0%100% | 10—100% | — | 3.0+258%100% | 0.8−5.8%100% | 0.9—100% | |
| Cost of revenue | 1.5—26.3% | — | — | — | — | — | — | — | — | — | |
| Research and development | 27−22.0%461% | 34+10.5%— | 31+7.3%888% | 29−25.2%2048% | 39r34+28.5%1291% | 30−37.9%301% | 49+25.5%— | 39+128%1291% | 17+59.4%2030% | 11—1199% | |
| Selling, general and administrative | 65+118%1117% | 30—— | — | — | — | — | — | — | — | — | |
| General and administrative | 65+118%1117% | 30+57.1%— | 19+10.1%543% | 17−20.3%1220% | 22r23−9.0%721% | 24+14.8%238% | 21+3.0%— | 20+83.7%671% | 11−17.7%1307% | 13—1495% | |
| Operating expenses | — | 64+26.8%— | 51−3.2%1447% | 52−43.6%3701% | 93+1.5%3095% | 91+18.6%914% | 77+26.0%— | 61+113%2040% | 29—3426% | — | |
| Total costs and expenses | 95+48.4%1637% | 64—— | — | — | — | — | — | 61+113%2040% | 29+15.8%3426% | 25—2786% | |
| Operating income | −89—−1537% | −64—— | −47—−1347% | −51—−3601% | −90—−2995% | −81—−814% | −77—— | −58—−1940% | −28—−3326% | −24—−2686% | |
| Interest expense and finance costs | 3.7−11.1%64.3% | 4.2+907%— | 0.4−43.2%11.9% | 0.7−79.9%52.1% | 3.7r3.7−11.2%122% | 4.1—41.1% | — | — | — | — | |
| Other non-operating income (expense) | 0.4−65.7%7.0% | 1.2−59.4%— | 2.9+1987%84.1% | 0.1—10.0% | — | — | — | — | 0.5−74.3%61.8% | 2.0—226% | |
| Income before tax | 71—1225% | −64—— | — | — | — | — | — | — | — | — | |
| Income tax | 0.1—1.7% | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | 71—1223% | −64—— | −54—−1548% | −40—−2807% | −85—−2831% | −84—−842% | −76—— | −57—−1890% | −27—−3264% | −22—−2460% | |
| Earnings per share, basic | 1.34—— | -1.55—— | -2.53—— | -5.53—— | -21.57r-0.86—— | -0.91—— | -1.51—— | -1.19—— | -0.66—— | -0.64—— | |
| Earnings per share, diluted | 1.01—— | -1.55—— | -2.53—— | -5.53—— | -0.86—— | -0.91—— | -1.51—— | -1.19—— | -0.66—— | -0.64—— | |
| Shares, weighted average (basic) | 53+29.0%— | 41+92.0%— | 21+172%— | 7.9+99.6%— | 3.9—— | — | — | — | — | 34—— | |
| Shares, weighted average (diluted) | 66+61.1%— | 41+92.0%— | 21+172%— | 7.9−92.0%— | 98+6.2%— | 93+84.0%— | 50+5.9%— | 48+14.1%— | 42+21.8%— | 34—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 78+236%35.7% | 23+61.4%21.4% | 14+1.8%22.6% | 14−56.8%22.1% | 33+161%41.4% | 13−90.3%8.3% | 129+589%57.9% | 19−86.4%10.8% | 138r138+99.2%77.1% | 69—62.3% | |
| Short-term investments | 113+51.9%51.4% | 74+97.0%68.3% | 38−0.5%59.0% | 38+214%59.1% | 12−85.3%15.2% | 82—54.5% | — | 66—38.0% | 0—0.0% | — | |
| Receivables | 6.1—2.8% | — | — | — | 3.0—3.8% | — | — | 0.1−24.3%0.0% | 0.1−13.7%0.1% | 0.1—0.1% | |
| Inventory | 5.5—2.5% | — | — | — | — | — | — | — | — | — | |
| Other current assets | 1.3+13.2%0.6% | 1.1+56.8%1.0% | 0.7+71.9%1.1% | 0.4−82.2%0.7% | 2.4r7.4−12.2%3.0% | 2.7−13.5%1.8% | 3.1−17.6%1.4% | 3.8+39.0%2.2% | 2.7+1665%1.5% | 0.2—0.1% | |
| Current assets | 205+103%93.3% | 101+80.9%92.6% | 56+5.0%87.1% | 53−5.7%82.7% | 56r55−42.4%70.7% | 98−26.2%64.6% | 132+49.0%59.3% | 89−36.8%50.9% | 141+103%78.6% | 69—62.5% | |
| Property, plant and equipment | 9.9+124%4.5% | 4.4+25.4%4.1% | 3.5−38.5%5.5% | 5.7−53.5%8.9% | 12+9.0%15.5% | 11−13.9%7.5% | 13+39.3%5.9% | 9.4+587%5.4% | 1.4+90.6%0.8% | 0.7—0.6% | |
| Right-of-use (leased) assets | 4.0+11.5%1.8% | 3.6−20.3%3.3% | 4.5−16.4%7.0% | 5.3−43.3%8.3% | 9.4+33.7%11.8% | 7.0−12.6%4.7% | 8.0—3.6% | — | — | — | |
| Goodwill | — | — | — | — | — | 320.0%21.5% | 320.0%14.5% | 320.0%18.6% | 320.0%18.2% | 32—29.2% | |
| Other intangible assets | — | — | — | 0−100%0.0% | 1.4−7.7%1.7% | 1.5−95.9%1.0% | 36−15.9%16.2% | 43+982%24.7% | 4.0−52.6%2.2% | 8.4—7.5% | |
| Total assets | 220+102%100% | 109+70.2%100% | 64−0.3%100% | 64−19.3%100% | 80−47.4%100% | 151−32.3%100% | 223+28.1%100% | 174−2.4%100% | 179+61.0%100% | 111—100% | |
| Accounts payable | 7.9+129%3.6% | 3.4+85.2%3.2% | 1.9+2.6%2.9% | 1.8−58.1%2.8% | 4.3−7.9%5.4% | 4.7+24.8%3.1% | 3.8−38.5%1.7% | 6.1+225%3.5% | 1.9r2.4−49.1%1.1% | 3.7—3.3% | |
| Debt due within a year | 12+106%5.6% | 5.9—5.4% | — | — | — | — | — | — | — | — | |
| Current liabilities | 30+78.3%13.5% | 17+23.6%15.2% | 13+72.5%21.0% | 7.8−53.2%12.1% | 17−60.4%20.9% | 42+8.4%27.8% | 39+90.1%17.3% | 20+263%11.7% | 5.6−32.4%3.1% | 8.3—7.5% | |
| Long-term debt | 7.8−40.1%3.6% | 13—12.0% | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 4.1+24.7%1.9% | 3.3−25.9%3.0% | 4.4−24.8%6.9% | 5.9−22.6%9.1% | 7.6+43.7%9.5% | 5.3−15.9%3.5% | 6.3—2.8% | — | — | — | |
| Total liabilities | 60−7.0%27.5% | 65+32.0%59.6% | 49+31.3%76.8% | 37+0.6%58.3% | 37r28−23.5%46.8% | 49+8.2%32.2% | 45+11.4%20.1% | 40+366%23.1% | 8.7−27.5%4.8% | 12—10.8% | |
| Retained earnings | −742—−338% | −813—−747% | −750—−1171% | −695—−1083% | −656—−824% | −571—−377% | −486—−218% | −410—−235% | −360—−201% | −332—−299% | |
| Shareholders' equity | 159+262%72.5% | 44+197%40.4% | 15−44.6%23.2% | 27−36.8%41.7% | 42r51−58.7%53.2% | 103−42.5%67.8% | 178+33.1%79.9% | 134−21.2%76.9% | 170+71.6%95.2% | 99—89.2% | |
| Total liabilities and equity | 220+102%100% | 109+70.2%100% | 64−0.3%100% | 64−19.3%100% | 80−47.4%100% | 151−32.3%100% | 223+28.1%100% | 174−2.4%100% | 179+61.0%100% | 111—100% | |
| Shares outstanding | 55+20.6%— | 46+72.1%— | 27+49.7%— | 18+201%— | 5.9r147−93.9%— | 96+15.0%— | 84+74.4%— | 48+2.3%— | 47+16.5%— | 40—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.5+27.2%43.8% | 2.0−12.4%— | 2.3−26.0%65.4% | 3.1−4.8%219% | 3.3−29.1%108% | 4.6−41.3%45.9% | 7.8+231%— | 2.4+218%78.7% | 0.7−10.2%88.5% | 0.8—92.8% | |
| Share-based compensation | 11+62.6%185% | 6.6+39.0%— | 4.8+56.3%136% | 3.1−65.8%216% | 8.9r5.3+52.3%297% | 5.9−20.2%58.5% | 7.3−10.3%— | 8.2+76.1%273% | 4.6−3.8%555% | 4.8—543% | |
| Cash from operating activities | −76—−1311% | −56—— | −37—−1057% | −43—−3075% | −66—−2189% | −35—−350% | −63—— | −39—−1305% | −23r−23—−2707% | −13—−1464% | |
| Capital expenditure | −8.0—−137% | −2.4—— | −0.3—−9.5% | −0.1—−9.2% | −4.2—−138% | −1.3—−13.4% | −6.3—— | −9.2—−308% | −0.9—−103% | −0.5—−58.4% | |
| Intangible assets bought | — | — | — | — | — | — | −0.2—— | −10—−342% | 0—0.0% | 0—0.0% | |
| Cash from investing activities | 105—1805% | −39−18965%— | 0.2—5.9% | −24−136%−1695% | 66—2202% | −84−240%−837% | 60—— | −85—−2838% | −0.9—−103% | −0.5—−58.4% | |
| Debt issued | — | 20—— | — | — | — | — | — | — | — | — | |
| Shares issued | 17+11.8%297% | 15+7.4%— | 14+12.2%412% | 13+59.5%908% | 8.1—268% | — | 17—— | — | — | — | |
| Cash from financing activities | 26−75.0%447% | 104+181%— | 37−14.2%1059% | 43+73.7%3053% | 25+1184%829% | 1.9−98.3%19.4% | 114+1980%— | 5.5−94.1%183% | 92+117%11040% | 43—4785% | |
| Change in cash | 55+516%941% | 8.9+3370%— | 0.3—7.3% | −24−196%−1717% | 25—842% | −117−205%−1168% | 111—— | −119−272%−3960% | 69r69+138%8230% | 29—3263% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 39—100% | 13—100% | 11+2745%100% | 8.7—100% | 5.4*—100% | 0*—— | 0.4—100% | — | — | — | — | — | 0*—— | |
| Cost of revenue | 14—34.9% | 5.7+1071%42.3% | 4.2—36.7% | 2.7—30.9% | 1.0*—19.3% | 0.5—— | — | — | — | — | — | — | — | |
| Research and development | 25−14.2%64.0% | 3.7−12.9%27.2% | 5.0−15.5%44.1% | 9.6−3.9%110% | 6.7*−25.4%124% | 4.2−52.8%— | 5.9−35.5%1486% | 9.9+37.9%— | 9.0*+21.9%— | 8.9—— | 9.2—— | 7.2—— | 7.4*—— | |
| Selling, general and administrative | 71+32.1%183% | 17−11.4%127% | 16−7.7%139% | 20+99.3%224% | 19*+145%347% | 19+202%— | 17+98.3%4287% | 9.8—— | 7.7*—— | 6.4—— | 8.6—— | — | — | |
| General and administrative | — | — | — | 20+99.3%224% | — | — | — | 9.8+37.4%— | 7.7*+31.7%— | 6.4—— | 8.6—— | 7.1—— | 5.8*—— | |
| Operating expenses | — | — | — | — | — | — | 23+29.8%5798% | 20+37.7%— | 17*+26.2%— | 15—— | 18—— | 14—— | 13*—— | |
| Total costs and expenses | 112+33.5%286% | 26+10.3%196% | 25+7.9%220% | 32+61.0%364% | 28*+69.9%523% | 24+56.5%— | 23—5798% | 20—— | 17*—— | 15—— | — | — | — | |
| Operating income | −73—−186% | −13—−96.4% | −14—−120% | −23—−264% | −23*—−423% | −24—— | −23—−5698% | −20—— | −17*—— | −15—— | −18—— | −14—— | −13*—— | |
| Interest expense and finance costs | 3.0−24.7%7.6% | 0.6−38.2%4.1% | 0.7−27.3%6.1% | 0.8−16.8%9.5% | 0.9*−18.3%16.3% | 0.9−18.2%— | 1.0−10.7%239% | 1.0+4.8%— | 1.1*+893%— | 1.1—— | 1.1—— | 1.0—— | 0.1*—— | |
| Other non-operating income (expense) | 0.1−90.9%0.2% | −0.0−102%−0.0% | −0.0−107%−0.1% | 0.1−64.5%0.6% | 0.1*−92.3%0.9% | 0.1−11.0%— | 0.1−60.3%22.3% | 0.1−13.0%— | 0.7*+210%— | 0.1—— | 0.2—— | 0.2—— | 0.2*—— | |
| Income before tax | −63−176%−161% | −4.8—−35.5% | −20−116%−177% | −17—−196% | −21*—−381% | −20—— | 124+1579%31086% | −12—— | −9.3*—— | −30—— | 7.4—— | — | — | |
| Income tax | −0.2—−0.5% | 0.0—0.1% | 0*−100%0.0% | 0.0—0.0% | −0.2*—−4.0% | −15—— | 16—3878% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −63−176%−160% | −4.8—−35.6% | −20−119%−177% | −17—−196% | −20*—−377% | −5.2—— | 109+1370%27208% | −12—— | −9.3*—— | −30—— | 7.4—— | −32—— | −17*—— | |
| Earnings per share, basic | — | -0.08—— | -0.35−117%— | -0.30—— | — | -0.10—— | 2.07+989%— | -0.24—— | — | -0.63—— | 0.19—— | -1.16—— | — | |
| Earnings per share, diluted | — | -0.08—— | -0.35−120%— | -0.30—— | — | -0.10—— | 1.71—— | -0.24—— | — | -0.63—— | -0.26—— | -1.16—— | — | |
| Shares, weighted average (basic) | 58+6.7%— | 58+6.7%— | 57+8.6%— | 57+13.7%— | — | 54+12.8%— | 53+31.3%— | 50+82.2%— | — | 48—— | 40—— | 27—— | — | |
| Shares, weighted average (diluted) | 58+6.7%— | 58+6.7%— | 57−14.4%— | 57+13.7%— | — | 54+12.8%— | 67+30.1%— | 50+82.2%— | — | 48—— | 51—— | 27—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 66—38.6% | 66−20.0%38.6% | 56−65.6%31.3% | 61+285%30.9% | 78+236%35.7% | 83+427%35.9% | 164+375%66.4% | 16−9.2%16.0% | 23+61.4%21.4% | 16—13.0% | 34—25.7% | 18—23.5% | 14—22.6% | |
| Short-term investments | 69—39.9% | 69−44.7%39.9% | 91+46.2%50.5% | 107+56.7%53.9% | 113+51.9%51.4% | 124+32.2%53.8% | 62−29.8%25.2% | 68+52.3%68.7% | 74+97.0%68.3% | 94—77.9% | 88—65.9% | 45—59.9% | 38—59.0% | |
| Receivables | 16—9.2% | 16—9.2% | 9.4—5.2% | 6.2—3.1% | 6.1—2.8% | — | — | — | — | — | — | — | — | |
| Inventory | 4.7—2.7% | 4.7−3.8%2.7% | 5.9+120%3.3% | 6.1—3.0% | 5.5—2.5% | 4.9—2.1% | 2.7—1.1% | — | — | — | — | — | — | |
| Other current assets | 1.9—1.1% | 1.9−14.0%1.1% | 1.9−7.1%1.1% | 2.0−3.0%1.0% | 1.3+13.2%0.6% | 2.2+120%1.0% | 2.1+71.6%0.8% | 2.0+11.0%2.0% | 1.1+56.8%1.0% | 1.0—0.8% | 1.2—0.9% | 1.8—2.4% | 0.7—1.1% | |
| Current assets | 158—91.7% | 158−27.0%91.7% | 165−29.1%91.7% | 183+108%92.2% | 205+103%93.3% | 216+91.8%93.5% | 232+84.5%94.3% | 88+32.1%88.7% | 101+80.9%92.6% | 113—93.4% | 126—94.0% | 67—89.2% | 56—87.1% | |
| Property, plant and equipment | 9.5—5.5% | 9.5−8.2%5.5% | 10+7.0%5.7% | 11+52.1%5.3% | 9.9+124%4.5% | 10+155%4.5% | 9.5+139%3.9% | 6.9+84.4%7.0% | 4.4+25.4%4.1% | 4.1—3.4% | 4.0—3.0% | 3.8—5.0% | 3.5—5.5% | |
| Right-of-use (leased) assets | 3.9—2.3% | 3.9−4.9%2.3% | 4.0−4.7%2.2% | 4.1−2.9%2.1% | 4.0+11.5%1.8% | 4.1+7.8%1.8% | 4.1+3.0%1.7% | 4.2+0.4%4.3% | 3.6−20.3%3.3% | 3.8—3.1% | 4.0—3.0% | 4.2—5.6% | 4.5—7.0% | |
| Total assets | 172—100% | 172−25.6%100% | 180−27.1%100% | 198+99.8%100% | 220+102%100% | 231+91.6%100% | 246+83.8%100% | 99+32.8%100% | 109+70.2%100% | 121—100% | 134—100% | 75—100% | 64—100% | |
| Accounts payable | 3.4—2.0% | 3.4−42.5%2.0% | 3.0−59.2%1.7% | 4.1−18.9%2.1% | 7.9+129%3.6% | 5.9+113%2.6% | 7.3+137%3.0% | 5.0+49.3%5.1% | 3.4+85.2%3.2% | 2.8—2.3% | 3.1—2.3% | 3.4—4.5% | 1.9—2.9% | |
| Debt due within a year | 12—6.9% | 12+33.3%6.9% | 13+140%7.4% | 13+63.6%6.7% | 12+106%5.6% | 8.9+100%3.8% | 5.6+150%2.3% | 8.1—8.2% | 5.9—5.4% | 4.4—3.7% | 2.2—1.7% | — | — | |
| Current liabilities | 28—16.1% | 28+24.9%16.1% | 25−28.1%13.8% | 31+72.6%15.6% | 30+78.3%13.5% | 22+20.4%9.6% | 35+105%14.0% | 18+51.3%18.1% | 17+23.6%15.2% | 18—15.3% | 17—12.6% | 12—15.9% | 13—21.0% | |
| Long-term debt | — | — | 1.7−88.2%0.9% | 4.8−57.3%2.4% | 7.8−40.1%3.6% | 11−23.5%4.7% | 14−13.2%5.7% | 11−38.4%11.2% | 13—12.0% | 14—11.8% | 16—12.0% | 18—24.2% | — | |
| Lease liabilities (non-current) | 3.5—2.0% | 3.5−18.6%2.0% | 3.6−9.4%2.0% | 3.8−6.5%1.9% | 4.1+24.7%1.9% | 4.3+25.0%1.8% | 4.0+31.8%1.6% | 4.1+0.8%4.1% | 3.3−25.9%3.0% | 3.4—2.8% | 3.0—2.3% | 4.0—5.4% | 4.4—6.9% | |
| Total liabilities | 46—26.8% | 46−23.1%26.8% | 51−37.8%28.7% | 54−7.6%27.0% | 60−7.0%27.5% | 60−20.0%25.9% | 83+36.0%33.6% | 58−30.8%58.3% | 65+32.0%59.6% | 75—62.0% | 61—45.3% | 84—112% | 49—76.8% | |
| Retained earnings | −784—−456% | −784—−456% | −779—−434% | −759—−382% | −742—−338% | −722—−312% | −716—−291% | −825—−831% | −813—−747% | −804—−667% | −774—−577% | −781—−1044% | −750—−1171% | |
| Shareholders' equity | 126—73.2% | 126−26.5%73.2% | 128−21.7%71.3% | 145+250%73.0% | 159+262%72.5% | 171+274%74.1% | 164+123%66.4% | 41—41.7% | 44+197%40.4% | 46—38.0% | 73—54.7% | −8.9—−11.9% | 15—23.2% | |
| Total liabilities and equity | 172—100% | 172−25.6%100% | 180−27.1%100% | 198+99.8%100% | 220+102%100% | 231+91.6%100% | 246+83.8%100% | 99+32.8%100% | 109+70.2%100% | 121—100% | 134—100% | 75—100% | 64—100% | |
| Shares outstanding | 57—— | 57+9.1%— | 57+11.7%— | 57+16.2%— | 55+20.6%— | 52+20.7%— | 51+23.0%— | 49+77.7%— | 46+72.1%— | 43—— | 42—— | 28—— | 27—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3.0+29.9%7.6% | 0.7+16.7%5.2% | 0.7+16.7%6.2% | 0.7+29.2%7.9% | 0.9*+60.1%15.9% | 0.6+20.0%— | 0.6+20.0%150% | 0.5+8.8%— | 0.5*+9.8%— | 0.5—— | 0.5—— | 0.5—— | 0.5*—— | |
| Share-based compensation | 12+14.7%29.9% | 2.8*+3.6%20.6% | 3.4+19.0%29.6% | 3.0+9.5%33.9% | 2.6*+30.9%47.2% | 2.7+49.1%— | 2.8+114%708% | 2.7+74.7%— | 2.0*+29.1%— | 1.8—— | 1.3—— | 1.5—— | 1.5*—— | |
| Cash from operating activities | −64—−163% | −8.3*—−61.6% | −17*—−154% | −20—−227% | −18*—−331% | −21*—— | −19*—−4696% | −18—— | −17*—— | −12*—— | −13*—— | −15—— | −9.2*—— | |
| Capital expenditure | −2.8—−7.1% | −0.2*—−1.6% | −0.5*—−4.2% | −0.9—−10.7% | −1.2*—−21.3% | −2.5*—— | −2.9*—−725% | −1.4—— | −0.6*—— | −0.4*—— | −0.7*—— | −0.7—— | −0.0*—— | |
| Cash from investing activities | 52−54.6%133% | 22*—161% | 16*−89.9%138% | 5.0+17.8%56.9% | 9.6*−49.4%176% | −65*—— | 156*—38972% | 4.2—— | 19*+63.7%— | −6.2*—— | −44*—— | −7.8—— | 12*—— | |
| Debt issued | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 20—— | — | |
| Debt repaid | — | −3.3*—−24.7% | −3.3*—−29.3% | −2.2—−25.5% | — | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | 0*−100%0.0% | 0*—— | 11*+196%2625% | 6.8+6.0%— | 5.5*−29.2%— | 0*—— | 3.5*—— | 6.4—— | 7.8*—— | |
| Cash from financing activities | −5.3−119%−13.5% | −3.3*−165%−24.8% | −3.3*−132%−29.3% | −2.2−133%−25.5% | 3.6*−32.0%66.7% | 5.2*—— | 10*−85.8%2624% | 6.8−73.4%— | 5.3*−28.8%— | −0.3*—— | 74*—— | 25—— | 7.5*—— | |
| Change in cash | −17−125%−43.4% | 10*—74.5% | −5.1*−103%−45.2% | −17—−196% | −4.8*−163%−88.3% | −81*—— | 148*+775%36900% | −7.4−341%— | 7.6*−21.8%— | −19*—— | 17*—— | 3.1—— | 9.8*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Abeona Therapeutics Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- License$3 M58%—
- Product(total)$2 M42%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Abeona Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Vishwas Seshadri | $4.0 M | $4.0 M | $1.6 M | $171 |
| 2024Vishwas Seshadri | $3.5 M | $4.0 M | $1.5 M | $181 |
| 2023Vishwas Seshadri | $2.8 M | $3.5 M | $1.3 M | $163 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Abeona Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Acquisition or sale completedMaterial agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Acquisition or sale completedResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2015 | $14 M | Private placement after listing | $10 to $50 million | 17 | equity | SEC |
| May 2015 | $10 M | Private placement after listing | $10 to $50 million | 2 | equity, options | SEC |
| Oct 2012 | $10 M | No. 2 | $10 to $50 million | 1 | equity | SEC |
| Nov 2011 | $6 M | No. 1 | $2 to $10 million | 14 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Abeona Therapeutics Inc. compares in Biotechnology
- Market cap$261 M · higher than 49% of 726
- Revenue$6 M · higher than 37% of 647
- P/E ratio3.7× · lower than 89% of 100
- Price / sales44.8× · lower than 19% of 339
- Price / book1.6× · lower than 64% of 534
- FCF yield-32.4% · higher than 33% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Abeona Therapeutics Inc.🇺🇸 | $261 M | 3.7× | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Abeona Therapeutics Inc.? Verify and update this profile — free
Show Abeona Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.